SEC Tracker
Get the app

Cadrenal Therapeutics CVKD

Cadrenal Therapeutics initiates strategic review

Form
8-K
Filed
Importance
Routine
  1. Initiated strategic process to evaluate value-maximizing opportunities
  2. Engaged Tungsten Advisors as exclusive financial advisor
  3. Pipeline includes CAD-1005, tecarfarin, frunexian, and CAD-2000
  4. No assurance of transaction outcomes

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Cadrenal Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Curis CRIS public float $25M, Jun 30, 2025
  2. Kala Bio KALA public float $25M, Jun 30, 2025
  3. Lexaria Bioscience LEXX public float $25M, Feb 28, 2025, over 18 months old
  4. Pulmatrix PULM public float $25M, Jun 30, 2025
  5. Dyadic International DYAI public float $24M, Jun 30, 2025